Renal Cell Carcinoma Roundtables
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion.
The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions.
The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies.
In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes.
Part one of the discussion covers adjuvant therapy in kidney cancer, patient selection, and balancing risks and benefits.
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
The panel shared their excitement for the road ahead in kidney cancer.
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
The panel discussed the impact of a subcutaneous formulation of nivolumab.
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
The panel discussed important takeaways from RCC studies presented at ASCO GU.
The panel shifts to focus on the current state of non-clear cell kidney cancer.
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
Dr. McDermott advocates for immune therapy in frontline RCC care.
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
The panel discusses treatment options in the refractory RCC setting.
The panel discusses what is most exciting to them in the frontline RCC field.
The panel discusses toxicity management and use of precision medicine.
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
Dr. Rini describes the CLEAR and KEYNOTE-426 studies presented at ASCO 2023.
The panel discusses the approach to frontline treatment selection for patients with RCC.
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
The panel discusses triplet combinations in development for RCC.
The panel discusses the disappointing results of the COSMIC-313 trial.
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
The panel shares how they treat frontline papillary kidney cancer.
The panel discusses treatment-related toxicities and when to consider stopping treatment.
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
The panel compares three treatment regimens.
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
The panel discusses the CheckMate 8Y8 clinical trial.
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.